Unlocking the Future of the Calcium Channel Blocker Market: Growth Rate, Key Trends, and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the calcium channel blocker market grown over the years?
The market size for calcium channel blockers has seen a robust growth in the past few years. The market is anticipated to expand from $15.56 billion in 2024 to $16.62 billion in 2025, experiencing a compound annual growth rate (CAGR) of 6.8%. The escalation during the historical phase was fostered by factors like the rising prevalence of cardiovascular diseases, an aging population, advancements in medical research, changing lifestyles, and heightened awareness.
What Is the forecasted market size and growth rate for the calcium channel blocker market?
In the upcoming years, the market size of calcium channel blockers is predicted to experience considerable growth, reaching $22.07 billion by 2029 with a compound annual growth rate (CAGR) of 7.4%. This forecasted growth can be credited to the escalating worldwide incidence of cardiovascular conditions, trends in individualized treatment, improved healthcare accessibility, indication expansions, regulatory authorizations, and market broadening. The projection period is characterized majorly by market development, technological progress, changes in regulatory frameworks, competitor analysis, patient choices, and increased awareness.
Get your calcium channel blocker market report here!
https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report
What are the major factors driving growth in the calcium channel blocker market?
An upward trend in cardiovascular diseases is anticipated to fuel the expansion of the calcium channel blocker market. These conditions, which affect the heart or blood vessels, often necessitate the use of calcium channel blockers (CCBs) to lower the likelihood of heart failure and stroke. Consequently, a rising rate of cardiovascular diseases suggests an increased need for these drugs. As an example, a study by the American College of Cardiology in August 2022 envisioned a surge in all four cardiovascular risk factors in the United States from 2025 to 2060. The highest anticipated surge is seen in diabetes, expected to grow by 39.3% to 55 million individuals. This is followed by dyslipidemia (rising by 27.6% to 126 million), hypertension (increasing by 25.1% to 162 million), and obesity (growing by 18.3% to 126 million). The report also pointed out an expected substantial rise in rates of cardiovascular diseases, primarily stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), ischemic heart disease (30.7% to 29 million), and heart attacks (16.9% to 16 million). Hence, the escalating rates of cardiovascular diseases are propelling the expansion of the calcium channel blocker market.
What key areas define the segmentation of the global calcium channel blocker Market?
The calcium channel blocker market covered in this report is segmented –
1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes
2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine
2) By Benzodiazepine: Diazepam
3) By Phenylalkylamine: Verapamil
4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp
What are the top market players propelling the growth of the calcium channel blocker industry?
Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.
What are the key trends shaping the future of the calcium channel blocker market?
The calcium channel blocker market is witnessing a growing trend of product innovation. To maintain their competitive edge, key players in the market are concentrating on the creation of novel products. An illustration of this is the June 2022 launch of Norliqva by CMP Pharma, a pharmaceutical manufacturer from the US. Norliqva, which is primarily an oral liquid version of besylate salt of amlodipine, is the first and sole long-acting calcium channel blocker of its kind. It is designed for people aged 6 and above who suffer from hypertension. Notably, Norliqva eliminates the challenges and inconsistencies linked to crushing or turning amlodipine tablets into a solution, promising equal dosing and bioequivalence. Furthermore, it is designed for a specific group of patients needing amlodipine who struggle or are incapable of swallowing.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9428
What regions are dominating the calcium channel blocker market growth?
North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Angiotensin Receptor Blockers (ARBs) Global Market Report 2024
Anti-Hypertensive Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report
Bipolar Disorder Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
